Javascript must be enabled to continue!
Correlation between CD133 and EGFR Expression with Grading of Ovarian Carcinoma
View through CrossRef
BackgroundOvarian carcinoma account for 90% of all malignant ovarian tumors. Epidermal Growth Factor Receptor (EGFR), also known asErbB1/HER1, has an important role in tumor cell proliferation. CD133 is a marker for hematopoietic stem cell and it is involved in tumorcell proliferation, self renewal and cell differentiation. The objective to analyze the expression of CD 133 and EGFR in high grade andlow grade ovarian carcinoma, and to determine the correlation between the expression of CD133 and EGFR expression in ovariancarcinoma.MethodsThe study was conducted with observational and cross sectional method on paraffin blocks of patients diagnosed as ovariancarcinoma from 1 January until 31 December 2017 in Dr. Soetomo Hospital. Ovarian carcinoma was divided into 2 grade, low gradeand high grade. Immunohistochemistry for EGFR and CD133 was performed. Immuno-reactive Score (IRS) was applied to evaluatethe expression of EGFR and CD133. The difference expression of CD133 and EGFR in low grade and high grade ovarian carcinomawas analyzed with Mann-Whitney test. Correlation between CD133 with EGFR was analyzed with Spearman test.ResultsThere were significant difference in expression of CD133 (p=0.0001) and EGFR (p=0.0005) in high grade and low grade OvarianCarcinoma. There was significant positive correlation between CD133 and EGFR expression in Ovarian Carcinoma (p=0.035; r=0.37)ConclusionExpression of CD133 and EGFR were higher in high grade ovarian carcinoma. The higher expression of CD133 will increaseexpression of EGFR in ovarian carcinoma. Both markers may be used as prognostic factor.
Indonesian Association of Pathologists
Title: Correlation between CD133 and EGFR Expression with Grading of Ovarian Carcinoma
Description:
BackgroundOvarian carcinoma account for 90% of all malignant ovarian tumors.
Epidermal Growth Factor Receptor (EGFR), also known asErbB1/HER1, has an important role in tumor cell proliferation.
CD133 is a marker for hematopoietic stem cell and it is involved in tumorcell proliferation, self renewal and cell differentiation.
The objective to analyze the expression of CD 133 and EGFR in high grade andlow grade ovarian carcinoma, and to determine the correlation between the expression of CD133 and EGFR expression in ovariancarcinoma.
MethodsThe study was conducted with observational and cross sectional method on paraffin blocks of patients diagnosed as ovariancarcinoma from 1 January until 31 December 2017 in Dr.
Soetomo Hospital.
Ovarian carcinoma was divided into 2 grade, low gradeand high grade.
Immunohistochemistry for EGFR and CD133 was performed.
Immuno-reactive Score (IRS) was applied to evaluatethe expression of EGFR and CD133.
The difference expression of CD133 and EGFR in low grade and high grade ovarian carcinomawas analyzed with Mann-Whitney test.
Correlation between CD133 with EGFR was analyzed with Spearman test.
ResultsThere were significant difference in expression of CD133 (p=0.
0001) and EGFR (p=0.
0005) in high grade and low grade OvarianCarcinoma.
There was significant positive correlation between CD133 and EGFR expression in Ovarian Carcinoma (p=0.
035; r=0.
37)ConclusionExpression of CD133 and EGFR were higher in high grade ovarian carcinoma.
The higher expression of CD133 will increaseexpression of EGFR in ovarian carcinoma.
Both markers may be used as prognostic factor.
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
Abstract
Background
2020 World Health Organization Classification of Female Genital Tumors removed ovarian seromucinous carcinoma as a distinct enti...
Abstract LB177: Visualization and targeting of CD133+ cancer stem cells in MASLD-related hepatocellular carcinoma
Abstract LB177: Visualization and targeting of CD133+ cancer stem cells in MASLD-related hepatocellular carcinoma
Abstract
Metabolic dysfunction-associated steatotic liver disease related hepatocellular carcinoma (MASLD-HCC) is an emerging malignancy. However, the identity and f...
Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.
Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.
Abstract
EGFR is an attractive target for the treatment of a variety of solid tumors because of its role as a driver oncogene and high level of expression. Four EGFR...
CD133+ human pulmonary adenocarcinoma cells induce apoptosis of CD8+T cells by highly expressed galectin-3
CD133+ human pulmonary adenocarcinoma cells induce apoptosis of CD8+T cells by highly expressed galectin-3
Purpose To investigate the expression and function of Galectin-3 (Gal-3) in CD133+ pulmonary adenocarcinoma. Methods CD133+ pulmonary adenocarcinoma cells were separated by MACS fr...
Impact of CD133 positive stem cell proportion on survival in patients with glioblastoma multiforme
Impact of CD133 positive stem cell proportion on survival in patients with glioblastoma multiforme
AbstractBackground. The aim of the study was to assess the impact of CD133-positive (CD133+) cancer stem cell proportions on treatment results of glioblastoma multiforme (GBM) pati...
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
8563 Background: There are limited reports on biomarker studies of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon...

